J&J’s guselkumab gets EU approval for ulcerative colitis, offering new hope for patients who don’t respond to current treatments.

Ireland has launched its first national clinical genomics study in paediatric oncology, by key stakeholders from the country’s healthcare, life sciences and academic research sectors. 

Boehringer Ingelheim and Tessellate Bio form a €500m partnership to develop precision therapies targeting ALT-positive cancers.

US drug tariffs may not hit branded prices hard, but generics and supply chains face disruption. Here’s what pharma leaders need to know.

FluidForm Bio’s 3D bioprinting tech keeps lab-grown cells alive five times deeper using vascular-like gelatin scaffolds.

The UK government has formally signed into law new clinical trial regulations, designed to modernise operations across the country.

CloudSpec speeds up lipid nanoparticle analysis, cutting lab times from hours to seconds for gene therapy and vaccine research.

The UK government has announced a significant new initiative to accelerate drug discovery and improve patient care in the country.  

Pharma must balance creativity with transparency to rebuild trust in 2025. VML Health’s report reveals key trends shaping expectations.

The European Commission has approved a new regimen from AstraZeneca, which combines the company’s durvalumab with chemotherapy for patients with resectable NSCLC

Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an expanded role.

From the latest news impacting the UK’s NHS to large industry acquisitions, March brought a range of impactful news.

Discover the latest pharma innovations, from needle-free vaccines to NHS data access and interactive case studies in medical education.

A gene therapy for heart failure with preserved ejection fraction (HFpEF) has shown promising early results.

This decision underscores the need for a preventative measure against the chlamydia, which affects millions worldwide.

A new study is challenging the belief that dementia is incompatible with modern work environments, with AI helping employees stay in work.